沙格列汀对多种口服降糖药物控制不良2型糖尿病的疗效及安全性研究  

Efficacy and safety of saxagliptin in patients with type 2 diabetes poorly controlled by oral antidiabetic drugs

作　　者：李顺斌[1] 邱蔚[1] 王文华[1] 施万春[1] 郑淑莺[1] 沈建国[2] 

机构地区：[1]湖州市中心医院内分泌科,313000 [2]浙江大学附属第一医院内分泌科

出　　处：《浙江医学》2014年第13期1141-1143,共3页Zhejiang Medical Journal

基　　金：湖州市自然科学基金项目(2010YZ14)

摘　　要：目的观察二肽基肽酶IV抑制剂沙格列汀对多种口服降糖药物治疗3个月以上血糖控制不良的2型糖尿病患者的疗效和安全性。方法入选研究对象90例,比较沙格列汀治疗前后空腹血糖、空腹胰岛素、服糖后1、2、3h血糖和胰岛素、糖化血红蛋白(HbA_1c)、TG、TC、LDL-C、HDL-C、胰高血糖素、BMI、胰高血糖素/胰岛素比值及稳态模型评估-胰岛素抵抗指数(HOMA-IR)。结果治疗后患者空腹血糖由(9.5±2.6)mmol/L降至(6.8±1.8)mmol/L、服糖后2h血糖由(14.8±3.2)mmol/L降至(8.9±2.3)mmol/L、HbA_1c由(8.4±2.2)%降至(7.0±1.3)%、服糖后2h胰高血糖素由(169.6±50.6)ng/L降至(101.4±40.8)ng/L,与治疗前比较均有统计学差异(均P<0.01),且无低血糖及体重增加等不良反应。结论沙格列汀能有效降低多种口服降糖药控制不良的2型糖尿病患者的血糖水平,具有良好的安全性。Objective To evaluate the efficacy and safety of dipeptidy1 peptidase- 4 inhibitor saxagliptin in patients with type 2 diabetes who were poorly control ed by multiple oral antidiabetic drugs. Methods Ninety type 2 diabetic patients who were poorly control ed by previous administration of oral antidiabetic drugs for at least 3 months were treated with saxagliptin. The changes of fasting plasma glucose （FPG）, fasting plasma insulin （FINS）, postprandial glucose and insulin （1, 2, 3h）, HbA1c, TG, TC, LDL- C, HDL- C, glucagon, BMI, glucagon/insulin and HOMA- IR were measured before and after treatment. Results FPG, 2h postprandial glucose（2h PPG）, HbA1c, 2h postprandial glucagon decreased significantly after saxagliptin treatment [（9.5±2.6） mmol/L vs （6.8±1.8）mmol/L, （14.8±3.2）mmol/Lvs （8.9±2.3）mmol/L, （8.4±2.2）%vs （7.0±1.3）%, （169.6±50.6）ng/L vs（101.4± 40.8）ng/L,respectively, al P〈0.01].There was no hypoglycemia, weight gain or other adverse reactions. Conclusion Saxagliptin can effectively reduce the blood sugar leve1s in type 2 diabetics poorly control ed by multiple oral antidiabetic drugs with an excellent safety profile.

关 键 词：二肽基肽酶类 拮抗剂 抑制剂 糖尿病 2型 

分 类 号：R587.1[医药卫生—内分泌]